Departure or Appointment of Directors or Certain Officers
→
6/17/25
Agreement
Entry into a Material Definitive Agreement
→
6/10/25
Vote
Submission of Matters to a Vote of Security Holders
→
4/14/25
Other
Other Events
→
6/28/24
Exec Change
Departure or Appointment of Directors or Certain Officers
→
↓
Prospectuses & Registrations
25 shown
Filed
Form
Description
7/25/25
POSASR
POSASR
→
7/25/25
S-8 POS
S-8 POS
→
7/25/25
S-8 POS
S-8 POS
→
7/25/25
S-8 POS
S-8 POS
→
7/25/25
S-8 POS
S-8 POS
→
7/25/25
S-8 POS
S-8 POS
→
↓
Filing History(344 filings)
TypeDateAccessionPeriodSize
SCHEDULE 13G
Aug 14, 2025
0000902664-25-003639
—
14.7 KB
SCHEDULE 13G/A
Aug 14, 2025
0000921895-25-002286
—
19.5 KB
15-12G
Aug 4, 2025
0001193125-25-17218015-12G
—
11.0 KB
EFFECT
Jul 28, 2025
9999999995-25-002366
—
1.7 KB
SCHEDULE 13G/A
Jul 28, 2025
0001415889-25-020385
—
26.8 KB
4
Jul 28, 2025
0001415889-25-020384
Jul 25, 2025
26.9 KB
4
Jul 28, 2025
0000950170-25-0992644
Jul 25, 2025
8.5 KB
4
Jul 28, 2025
0000950170-25-0992634
Jul 25, 2025
18.6 KB
4
Jul 28, 2025
0000950170-25-0992624
Jul 25, 2025
20.9 KB
4
Jul 28, 2025
0000950170-25-0992614
Jul 25, 2025
20.9 KB
4
Jul 28, 2025
0000950170-25-0992604
Jul 25, 2025
32.2 KB
4
Jul 28, 2025
0000950170-25-0992594
Jul 25, 2025
20.8 KB
4
Jul 28, 2025
0000950170-25-0992584
Jul 25, 2025
13.1 KB
4
Jul 28, 2025
0000950170-25-0992574
Jul 25, 2025
8.5 KB
4
Jul 28, 2025
0000950170-25-0992564
Jul 25, 2025
8.6 KB
4
Jul 28, 2025
0000950170-25-0992544
Jul 25, 2025
22.8 KB
4
Jul 28, 2025
0000950170-25-0992554
Jul 25, 2025
23.2 KB
4
Jul 28, 2025
0000950170-25-0992524
Jul 25, 2025
8.5 KB
4
Jul 28, 2025
0000950170-25-0992534
Jul 25, 2025
10.6 KB
4
Jul 28, 2025
0000950170-25-0992514
Jul 25, 2025
8.5 KB
POS AM
Jul 25, 2025
0001193125-25-165532POS AM
—
20.1 KB
8-K
Jul 25, 2025
0001193125-25-1654628-K
Jul 23, 2025
268.1 KB
POSASR
Jul 25, 2025
0001193125-25-165139POSASR
—
20.2 KB
S-8 POS
Jul 25, 2025
0001193125-25-165135S-8 POS
—
23.5 KB
S-8 POS
Jul 25, 2025
0001193125-25-165134S-8 POS
—
23.5 KB
25 filings shown
Verve Therapeutics, Inc. — SlamSEC
Proxies
8 shown
Filed
Form
Description
4/25/25
DEFA14A
DEFA14A
→
4/25/25
DEF 14A
DEF 14A
→
4/26/24
DEFA14A
DEFA14A
→
4/26/24
DEF 14A
DEF 14A
→
4/28/23
DEFA14A
DEFA14A
→
4/28/23
DEF 14A
DEF 14A
→
↓
Ownership
40 shown
Filed
Form
Description
7/28/25
4
4
→
7/28/25
4
4
→
7/28/25
4
4
→
7/28/25
4
4
→
7/28/25
4
4
→
7/28/25
4
4
→
↓
Other Filings
33 shown
Filed
Form
Description
8/14/25
SCHEDULE 13G
SCHEDULE 13G
→
8/14/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
8/4/25
15-12G
15-12G
→
7/28/25
EFFECT
EFFECT
→
7/28/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
7/25/25
POS AM
POS AM
→
↓
VERVE-101 and VERVE-102 are an experimental gene therapy developed by Verve Therapeutics that targets the PCSK9 gene and is intended to reduce blood cholesterol levels. It works on the same protein as the cholesterol-lowering drugs known as PCSK9 inhibitors but, unlike them, is permanent.